Close Menu

Bio-Rad

The firm aims to launch the new assay in the first quarter of next year and plans to develop other products for single-cell sequencing library prep.

The company is collecting validation evidence it intends to submit to the FDA next year, which will also support launch of  the test as an LDT.

The company said Q2 sales increased 11 percent on a currency-neutral basis, driven by growth in both its Life Science and Clinical Diagnostics segments.

Bio-Rad tallied net sales of $551.5 million compared to $500.1 million in Q1 2017, driven by growth in both its Life Science and Clinical Diagnostics businesses.

The assay could provide detection of HBV infection at early stages, potentially preventing progression to cirrhosis or hepatocellular carcinoma.

As previously disclosed, Bio-Rad's accounting firm needs more time to complete its audit and the company plans to file the form as soon as possible.

The GenomeWeb Index outperformed the Nasdaq Biotechnology Index, which lost 5 percent in February, but lost the same amount as the Dow.

The firm saw an increase in sales for both the life science and clinical diagnostics segments.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.